Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals. The ev…
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Single case report describes durable response to nivolumab in relapsed ALK+ large B-cell lymphoma
Can a common immunotherapy drug help a rare, aggressive lymphoma?
A case report describes one adult patient with stage IV, relapsed/refractory ALK+ large B-cell lymphoma who received off-label nivolumab. Th…
A rare, aggressive lymphoma that failed four treatments responded rapidly to an immunotherapy drug not approved for this cancer, offering ho…
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Post hoc analysis links TMB ≥9 or BRAF-V600E to longer PFS with chemo-nivolumab in MSS/pMMR mCRC
Could two simple blood tests help predict which colon cancer patients benefit from immunotherapy?
A post hoc analysis of the METIMMOX RCT in patients with metastatic MSS/pMMR colorectal cancer found that in the experimental arm (alternati…
Two simple blood tests and tumor markers can predict which colon cancer patients live longer on immunotherapy combined with chemotherapy.
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns.
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…
Nivolumab+ipilimumab shows 5-year OS benefit (14% vs 6%) vs chemo in unresectable pleural mesothelioma
Can immunotherapy help people with advanced mesothelioma live longer? Five-year results show it can.
In the 5-year follow-up of CheckMate 743, nivolumab plus ipilimumab demonstrated continued overall survival benefit versus chemotherapy in u…
Five years after starting treatment, 14% of advanced mesothelioma patients survived on immunotherapy versus 6% on chemotherapy, proving last…
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
Can New Treatments Help Fight HIV-Related Anal Cancer More Effectively?
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-r…
A new trial tests gentler radiation and chemotherapy for low-risk HIV anal cancer, while adding immunotherapy for high-risk cases to improve…